Samsung Medical Center
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 501
- Market Cap
- -
Feasibility of Mutational Analysis of Non-Small Cell Lung Cancer (NSCLC) Using Low-volume Lung Aspirates
Withdrawn
- Conditions
- Lung Cancer
- Interventions
- Procedure: biopsy
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT01482572
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Plasma Adiponectin Level and Vascular Endothelial and Smooth Muscle Cell Function in Children With Prader-Willi Syndrome
Completed
- Conditions
- Prader-Willi SyndromeObesity
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 51
- Registration Number
- NCT01479322
Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal
Not Applicable
Completed
- Conditions
- Epiretinal Membrane
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2011-11-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 52
- Registration Number
- NCT01474655
Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma
Phase 2
Completed
- Conditions
- Advanced or Recurrent Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: Capecitabine/Cisplatin(XP)Drug: Capecitabine/Paditaxel(XG)
- First Posted Date
- 2011-11-18
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT01474642
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Elongation of Foveal Tissue After Macular Hole Surgery
Not Applicable
Completed
- Conditions
- Macular Holes
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT01471912
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma
Completed
- Conditions
- Metastatic Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 239
- Registration Number
- NCT01472419
A Prospective Study of Pharmacogenetic Factors and Gene Expression Profile
- Conditions
- Colon Cancer
- First Posted Date
- 2011-11-16
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 2660
- Registration Number
- NCT01472601
- Locations
- π°π·
Samsung medical Center, Seoul, Korea, Republic of
Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma
Phase 3
- Conditions
- Biliary Tract (Intrahepatic, Extrahepatic Cholangiocarcinoma, Gall Bladder) Cancer
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 240
- Registration Number
- NCT01470443
- Locations
- π°π·
Samsung medical Center, Seoul, Korea, Republic of
Pharmacogenomic Study (Adjuvant Chemotherapy)
Completed
- Conditions
- Gastric Cancer
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 792
- Registration Number
- NCT01470404
- Locations
- π°π·
Samsung Medical Center, Seoul, Korea, Republic of
Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT01470742
- Locations
- π°π·
Samsung medical Center, Seoul, Korea, Republic of
Β© Copyright 2025. All Rights Reserved by MedPath